EIF5A2 and esophageal squamous cell carcinoma: N1‐guanyl‐1,7‐diaminoheptane (GC7) has the ability to inhibit EIF5A2 activation; therefore, GC7 may be considered as part of a combination therapy to enhances the sensitivity of ESCC patients to chemotherapy.215